Skip to Main Content


Skip Nav Destination

Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma

Clin Cancer Res (2022) 28 (8): 1603–1613.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal